The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CP-31398 inhibited ubiquitination and degradation of p53457 and activated BAX independently of p53 to promote apoptosis of tumor cells.455”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [455]
In the citing paper
“For example, CP-31398 was initially thought to maintain the wild-type conformation of the mutant p53,454 but was shown to be unable to bind p53 in a different lab.455”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [455]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 2×
“The crystal structure of wild-type core domain complexed with DNA (Cho et al., 1994) provides a structural basis for analysing the e ects of mutation.”
BackgroundHot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K.-B., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 221
Self-citation
Research works printed but not linked: 12
- Asker C, Wiman KG, Selivanova G . 1999 Biochem. Biophys. Res. Commun. 265: 1–6 · DOI
- Bullock AN, Fersht AR . 2001 Nature Rev. Cancer 1: 68–76 · DOI · Paper page
- Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP, Fersht AR . 1997 Proc. Natl. Acad. Sci. USA 94: 14338–14342 · DOI · Paper page
- Bullock AN, Henckel J, Fersht AR . 2000 Oncogene 19: 1245–1256 · DOI · Paper page
- Foster BA, Coffey HA, Morin MJ, Rastinejad F . 1999 Science 286: 2507–2510 · DOI · Paper page
- Jayaraman L, Freulich E, Prives C . 1997 Methods Enzymol. 283: 245–256 · DOI
- Ko LJ, Prives C . 1996 Genes Dev. 10: 1054–1072 · DOI · Paper page
- Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH . 1994 Structural Biol. 1: 877–890 · DOI · Paper page
- Nikolova PV, Henckel J, Lane DP, Fersht AR . 1998 Proc. Natl. Acad. Sci. USA 95: 14675–14680 · DOI · Paper page
- Nikolova PV, Wong K-B, DeDecker B, Henckel J, Fersht AR . 2000 EMBO J. 19: 370–378 · DOI · Paper page
- Prives C, Hall PA . 1999 J. Pathol. 187: 112–126 · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
- Selivanova G, Iotsova V, Kiseleva E, Strom M, Bakalkin G, Grafstrom RC, Wiman KG . 1996 Nucleic Acids Res. 24: 3560–3567 · DOI · Paper page
Cited by
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Self-citationAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Self-citationIs allostery an intrinsic property of all dynamic proteins?
Gunasekaran, K., Ma, B., & Nussinov, R. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20232 · Cited by 879
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
Self-citationThe p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Self-citationTargeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Self-citationProtein Folding and Mechanisms of Proteostasis
Díaz-Villanueva, J., Díaz-Molina, R., & García-González, V. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817193 · Cited by 338
The role of p53 in chemosensitivity and radiosensitivity
El-Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206949 · Cited by 337
Targeting Oncogenic Mutant p53 for Cancer Therapy
Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 337
Farnebo, M., Bykov, V. J. N., & Wiman, K. G. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.152 · Cited by 268
Self-citationReactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Self-citationCP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207198 · Cited by 158
Towards an understanding of the role of p53 in adrenocortical carcinogenesis
Wasserman, J. D., Zambetti, G. P., & Malkin, D. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.010 · Cited by 84
“Finally, the C-terminus (aa 325–356) is required for tetramerization and contains multiple nuclear localization sequences as well as multiple lysine residues which are key to regulating p53 activity. p53 has central roles in mediating the cellular response to genotoxic stress (such as ionizing radiation, free radicals…”
InfluentialTranslational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
“However, NMR studies failed to detect a direct interaction of CP31398 with p53 (Rippin et al., 2002).”
BackgroundSmall-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Rippin, T. M., Bykov, V. J. N., Freund, S. M. V., Selivanova, G., Wiman, K. G., & Fersht, A. R.
- Venue
- Oncogene
- Published
- 2002-03-28
- Volume
- 21
- Issue
- 14
- Pages
- 2119-2129
- ISSN
- 0950-9232
- 1476-5594
- Cited by
- 151
- References
- 3
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.